Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Tango Therapeutics Inc (NASDAQ: TNGX) closed at $6.71 in the last session, down -1.61% from day before closing price of $6.82. In other words, the price has decreased by -$1.61 from its previous closing price. On the day, 0.72 million shares were traded. TNGX stock price reached its highest trading level at $6.85 during the session, while it also had its lowest trading level at $6.6423.
Ratios:
We take a closer look at TNGX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $11.
On July 17, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Third Rock Ventures IV, L.P. sold 302,194 shares for $7.00 per share. The transaction valued at 2,115,358 led to the insider holds 15,456,881 shares of the business.
Third Rock Ventures IV, L.P. bought 302,194 shares of TNGX for $2,085,139 on Aug 22 ’25. On Aug 19 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 1,100,000 shares for $7.01 each. As a result, the insider received 7,712,760 and left with 15,759,075 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 746554624 and an Enterprise Value of 600779264. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.72 while its Price-to-Book (P/B) ratio in mrq is 5.51. Its current Enterprise Value per Revenue stands at 24.727 whereas that against EBITDA is -3.881.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.65, which has changed by -0.38609332 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $11.92, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 6.38%, while the 200-Day Moving Average is calculated to be 91.77%.
Shares Statistics:
According to the various share statistics, TNGX traded on average about 2.57M shares per day over the past 3-months and 1366690 shares per day over the past 10 days. A total of 110.87M shares are outstanding, with a floating share count of 64.92M. Insiders hold about 43.62% of the company’s shares, while institutions hold 73.25% stake in the company. Shares short for TNGX as of 1755216000 were 25156715 with a Short Ratio of 9.80, compared to 1752537600 on 21525555. Therefore, it implies a Short% of Shares Outstanding of 25156715 and a Short% of Float of 27.13.
Earnings Estimates
The stock of Tango Therapeutics Inc (TNGX) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $41.34M. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M
